Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/aps.2015.68 http://scihub22266oqcxt.onion/10.1038/aps.2015.68 C4648176!4648176!26299952     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Pharmacol+Sin 2015 ; 36 (10): 1163-9 Nephropedia Template TP {{tp|p=26299952|t=2015. Toward rapamycin analog (rapalog)-based precision cancer therapy |pdf=|usr=}}{{26299952}} gab.com Text Toward rapamycin analog (rapalog)-based precision cancer therapy JO: Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=26299952 #FOAvip Rapamycin and its analogs (rapalogs) are the first generation of mTOR inhibitors, which have the same molecular scaffold, but different physiochemical properties. Rapalogs are being tested in a wide spectrum of human tumors as both monotherapy and a component of combination therapy. Among them, temsirolimus and everolimus have been approved for the treatment of breast and renal cancer. However, objective response rates with rapalogs in clinical trials are modest and variable. Identification of biomarkers predicting response to rapalogs, and discovery of drug combinations with improved efficacy and tolerated toxicity are critical to moving this class of targeted therapeutics forward. This review focuses on the aberrations in the PI3K/mTOR pathway in human tumor cells or tissues as predictive biomarkers for rapalog efficacy. Recent results of combinational therapy using rapalogs and other anticancer drugs are documented. With the rapid development of next-generation genomic sequencing and precision medicine, rapalogs will provide greater benefits to cancer patients. Twit Text FOAVip Toward rapamycin analog (rapalog)-based precision cancer therapy ????Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=26299952 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26299952 #FOAvip English Wikipedia <ref>{{Cite pmid|26299952}}</ref> Toward rapamycin analog (rapalog)-based precision cancer therapy #MMPMID26299952 Meng Lh; Zheng XS Acta Pharmacol Sin 2015[Oct]; 36 (10): 1163-9 PMID26299952show ga Rapamycin and its analogs (rapalogs) are the first generation of mTOR inhibitors, which have the same molecular scaffold, but different physiochemical properties. Rapalogs are being tested in a wide spectrum of human tumors as both monotherapy and a component of combination therapy. Among them, temsirolimus and everolimus have been approved for the treatment of breast and renal cancer. However, objective response rates with rapalogs in clinical trials are modest and variable. Identification of biomarkers predicting response to rapalogs, and discovery of drug combinations with improved efficacy and tolerated toxicity are critical to moving this class of targeted therapeutics forward. This review focuses on the aberrations in the PI3K/mTOR pathway in human tumor cells or tissues as predictive biomarkers for rapalog efficacy. Recent results of combinational therapy using rapalogs and other anticancer drugs are documented. With the rapid development of next-generation genomic sequencing and precision medicine, rapalogs will provide greater benefits to cancer patients. äToward rapamycin analog (rapalog)-based precision cancer therapy (epmc).pdf DeepDyve Pubget Overpricing